BioMarin Pharma (BMRN) Tops Q3 EPS by 38c; raises guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $55.90 +2.21%
Revenue Growth %: +13.2%
Financial Fact:
INCOME FROM OPERATIONS: -60.09M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +13.2%
Financial Fact:
INCOME FROM OPERATIONS: -60.09M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of $0.91, $0.38 better than the analyst estimate of $0.53. Revenue for the quarter came in at $746 million versus the consensus estimate of $703.14 million.
GUIDANCE:
BioMarin Pharma sees FY2024 EPS of $3.25-$3.35, versus the consensus of $3.22. BioMarin Pharma sees FY2024 revenue of $2.79-2.825 billion, versus the consensus of $2.799 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- Groq raises $650m to expand AI inference cloud operations
- AeroVironment restates quarterly financials, citing $89M goodwill error
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
